West Pharmaceutical Services (WST) Total Current Liabilities (2009 - 2026)

West Pharmaceutical Services has disclosed Total Current Liabilities across 18 years of filings, most recently posting $640.5 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 5.94% year-over-year to $640.5 million; the TTM figure through Jun 2026 stood at $640.5 million (up 5.94% YoY), while the FY2025 annual figure was $654.9 million, up 18.99% from the prior year.
• Total Current Liabilities came in at $640.5 million for Q2 2026 at West Pharmaceutical Services, down from $674.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $674.0 million in Q1 2026 to a low of $456.7 million in Q3 2022.
• Average Total Current Liabilities over 5 years is $581.2 million, with a median of $574.9 million recorded in 2022.
• Year-over-year, Total Current Liabilities grew 29.44% in 2023 and dropped 18.77% in 2025.
• Over 5 years, Total Current Liabilities stood at $519.0 million in 2022, then climbed by 29.44% to $671.8 million in 2023, then fell by 18.07% to $550.4 million in 2024, then climbed by 18.99% to $654.9 million in 2025, then dropped by 2.2% to $640.5 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $640.5 million in Q2 2026, $674.0 million in Q1 2026, and $654.9 million in Q4 2025.